Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Net Cash Flow (2016 - 2025)

Corcept Therapeutics' Net Cash Flow history spans 10 years, with the latest figure at -$4.6 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 47.99% year-over-year to -$4.6 million; the TTM value through Dec 2025 reached -$8.6 million, down 12.46%, while the annual FY2025 figure was -$8.6 million, 12.46% down from the prior year.
  • Net Cash Flow for Q4 2025 was -$4.6 million at Corcept Therapeutics, down from $22.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $233.6 million in Q1 2023 and bottomed at -$127.6 million in Q2 2023.
  • The 5-year median for Net Cash Flow is -$2.7 million (2021), against an average of $2.1 million.
  • The largest annual shift saw Net Cash Flow surged 2107.68% in 2022 before it plummeted 506.64% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at -$17.1 million in 2021, then soared by 194.23% to $16.1 million in 2022, then surged by 45.42% to $23.4 million in 2023, then plummeted by 137.9% to -$8.9 million in 2024, then surged by 47.99% to -$4.6 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Net Cash Flow are -$4.6 million (Q4 2025), $22.7 million (Q3 2025), and $11.1 million (Q2 2025).